Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America

Comments
Loading...
  • Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation INCY to distribute tafasitamab and pemigatinib (Pemazyre) in Latin America.
  • Related: Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada.
  • Under the agreement terms, Incyte will be responsible for developing, manufacturing, and supplying tafasitamab and pemigatinib. 
  • Knight will be responsible for seeking the necessary regulatory approvals distributing both medicines in Latin America.
  • Tafasitamab, in combination with lenalidomide, is approved in the U.S and Europe for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). 
  • Pemigatinib is approved in the U.S., Europe, and Japan for locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. 
  • Read Next: Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD.
  • Price Action: INCY stock is down 0.10% at $69.52 during the market session on the last check Thursday.
Overview Rating:
Good
62.5%
Technicals Analysis
100
0100
Financials Analysis
40
0100
Overview
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!